Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BMS-986218 |
Trade Name | |
Synonyms | BMS986218|BMS 986218 |
Drug Descriptions |
BMS-986218 is a 2nd generation antibody that targets CTLA4, resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33). |
DrugClasses | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C135633 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BMS-986218 | BMS-986218 | 0 | 2 |
BMS-986218 + Degarelix | BMS-986218 Degarelix | 0 | 1 |
BMS-986218 + Docetaxel | BMS-986218 Docetaxel | 0 | 1 |
BMS-986218 + Docetaxel + Nivolumab | BMS-986218 Docetaxel Nivolumab | 0 | 1 |
BMS-986218 + Nivolumab | BMS-986218 Nivolumab | 0 | 3 |